Archive · 20 Jan 2026
Pharma Sector Seeks Budget Support for Growth
The pharma and healthcare sectors in India want the government to support them in the upcoming budget.
They need money for research and development (R&D), better hospitals, and making medicines and medical equipment in India.
K Satish Reddy, the head of Dr Reddy’s Laboratories, says this will help India make better medicines and treatments.
Other experts also want the government to help with taxes, training people for healthcare jobs, and making sure everyone can get good healthcare.
The goal is to make India a leader in making high-quality medicines and healthcare services.
The pharma sector seeks a structured funding framework for innovation and R&D to become a $500 billion industry by 2047.
Healthcare industry demands infrastructure expansion, capex allocation, tax deductions, and policy support in Budget 2026.
Experts emphasize the need for domestic manufacturing, workforce expansion, and improved healthcare access in Tier 2 and Tier 3 cities.
Pharma companies seek competitive tax rates, support for patents, and incentives for Make in India and FDI in pharma manufacturing.
Sanjeev Krishan of PwC India suggests focusing on expenditure quality, productivity, skill development, and better utilization of free trade agreements.
- Who
- K Satish Reddy, Sudarshan Jain, Dr Mukesh Batra, Dr Sabine Kapasi, Dr Ramesh Kancharla, Dev Tripathy, Himanshu Baid, Sanjeev Krishan
- What
- Pharma and healthcare sectors seek budget support for innovation, infrastructure, and competitive manufacturing
- When
- January 19, 2026
- Where
- India
- Why
- To advance innovation, improve patient access, achieve a $500 billion industry by 2047, and strengthen India's competitive edge
- Sector
- Pharmaceutical
- Key Figures
- K Satish Reddy, Sudarshan Jain, Dr Mukesh Batra, Dr Sabine Kapasi, Dr Ramesh Kancharla, Dev Tripathy, Himanshu Baid, Sanjeev Krishan
- Company
- Dr Reddy’s Laboratories, Dr Batra’s Healthcare, Enira Consulting, Rainbow Children’s Medicare, Philips Indian Subcontinent, Poly Medicure, PwC India
- Expected Outcome
- Deepened innovation, R&D, infrastructure expansion, and competitive manufacturing
- Vision
- India as a $500 billion pharma industry by 2047
- Key Focus
- Structured funding framework, domestic manufacturing, healthcare access, and tax incentives
- Date
- January 19, 2026
Sources
Budget 2026: Structured funding framework will deepen innovation, R&D: Satish Reddy
Union Budget 2026–27: Healthcare leaders urge govt to raise spending, fix rural gaps
Budget 2026: Healthcare sector looks for infrastructure expansion, capex allocation, tax deductions and policy support
Davos 2026: Union Budget must focus on spending impact, says PwC India Chairperson Sanjeev Krishan
₹300-crore grants, plug-and-play park: How Chhattisgarh is wooing pharma, biotech investors
